Marius Ringelstein

Join neurologists John Pluvinage, Andrew McKeon, Martin Tichler, Jolt Elesch, and Marius Ringelstein in a fascinating discussion on autoimmune neurology. Pluvinage dives into anti-CD320 antibodies and their clinical significance. McKeon reveals insights about paraneoplastic CAMKV autoimmune encephalitis. Tichler highlights long-term outcomes in anti-NMDAR encephalitis patients. Elesch examines mortality rates in AQP4 antibody-positive neuromyelitis optica, while Ringelstein evaluates the efficacy of Eculizumab in clinical settings. Tune in for cutting-edge insights in neurology!

Dr. Marius Ringelstein, a neurologist from Heinrich Heine University specializing in Neuromyelitis Optica Spectrum Disorders (NMOSD), and Dr. Ilya Ayzenberg from Rory University discuss the use of Eculizumab in treating NMOSD. They emphasize the drug's effectiveness and safety, particularly concerning vaccination against meningococcal infections for patients. The conversation highlights vaccination protocols and the timing of treatments, as well as the promising alternative of Ravulizumab for less frequent dosing. Practical insights shape their review of patient-centered care.